Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Montserrat Vázquez-BautistaLaboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0009-0002-4651-7892
Laura Morales-LunaLaboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.
Verónica Pérez de la CruzNeurobiochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City 14269, Mexico.ORCID 0000-0002-1451-8754
Rosa Angélica Castillo-RodríguezCentro de Investigación en Ciencia Aplicada y Tecnología Avanzada (CICATA) Unidad Morelos, Instituto Politécnico Nacional, Boulevard de la Tecnología, 1036 Z-1, P 2/2, Atlacholoaya 62790, Mexico.
José Antonio Velázquez-AragónLaboratorio de Oncología Experimental, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico.ORCID 0000-0002-3617-8148
Sergio Enríquez-FloresLaboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0003-2058-5707
Luis Antonio Flores-LópezSecretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI)-Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0002-2332-4361
Elizabeth Hernández-UrzúaLaboratorio de Toxicología Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.
Víctor Martínez-RosasDepartamento de Ingeniería Química y Bioquímica, Instituto Tecnológico de Milpa Alta, Tecnológico Nacional de México, Mexico City 12300, Mexico.ORCID 0000-0001-6137-6499
Carlos Wong-BaezaLaboratorio de Biomembranas, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City 11350, Mexico.ORCID 0000-0002-6262-8106
Isabel Baeza-RamírezLaboratorio de Biomembranas, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City 11350, Mexico.ORCID 0000-0001-8752-252X
Gabriel Navarrete-VázquezFacultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico.ORCID 0000-0001-5344-4762
Benjamin PinedaNeuroimmunology Laboratory, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City 14269, Mexico.ORCID 0000-0002-1455-312X
Beatriz Hernández-OchoaLaboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City 06720, Mexico.
Saúl Gómez-ManzoLaboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.ORCID 0000-0003-2095-9182
Funding
Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT) Ciencia de Frontera 2023 CF-2023-I-811E022 Program, National Institute of Pediatrics, Mexico City, Mexico (Recursos Fiscales para la Investigación INP 016/2023Fondos Federales HIM/2019/036 SSA. 1595
6 · The paper itself
Abstract
Hypoxia and activation of the pentose phosphate pathway (PPP), as well as overexpression of glucose-6-phosphate dehydrogenase (G6PD), are hallmark features of glioblastomas (GBM), contributing significantly to tumor progression metabolic adaptation and drug resistance. This study aimed to evaluate the cytotoxic effects of nine synthetic compounds incorporating annulated benzimidazole and nitrothiazole scaffolds in two glioblastoma cell lines (A172 and U87-MG) under both normoxic and hypoxic conditions. Three compounds (BZM-7, BZM-9, and CNZ-3) demonstrated potent anticancer activity, with CNZ-3 exhibiting the highest efficacy, particularly in hypoxia. The study further investigated the effects of these compounds on the expression of the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting G6PD with Benzimidazole and Thiazole Derivatives Suppresses · full record | OpenQuestion